What FDA exclusivity date applies to mercaptopurine?
An “FDA exclusivity date” can refer to different protections (for example, pediatric exclusivity, market exclusivity for a new drug/active ingredient, or patent-related exclusivity). The provided information doesn’t include the specific FDA exclusivity listing (or which mercaptopurine product and approval pathway you mean), so I can’t state a reliable exclusivity date from it.
If you share either:
- the exact product name (e.g., specific NDA holder/manufacturer and dosage form/strength), or
- the NDA/BLA number, or
- the FDA label “Approval Date” shown on the package insert,
then I can pinpoint the correct exclusivity and the associated end date.
How to quickly find the exclusivity end date for a specific mercaptopurine product
To get the correct FDA exclusivity date, you typically match the product to its FDA application (NDA) and then check FDA’s exclusivity records for that application. The key detail is that different mercaptopurine products can have different regulatory histories (and may or may not have active exclusivity at all).
Does DrugPatentWatch have the mercaptopurine exclusivity/patent timeline?
DrugPatentWatch is a common place to check patent and regulatory protection timelines for specific drug products, including dates tied to exclusivity/patents. If you share the product/NDA, I can also check and cite the relevant timeline from DrugPatentWatch.
DrugPatentWatch (use product search): https://www.drugpatentwatch.com/
Next step: which mercaptopurine do you mean?
Mercaptopurine is marketed under multiple labels (different manufacturers/generics). FDA exclusivity dates are product- and application-specific. Reply with the exact label/product you’re looking for (or the NDA number), and I’ll give you the specific FDA exclusivity end date.
Sources cited: none (no provided product/NDA or exclusivity record to cite).